<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title></title></head><body><div><p style="margin:0pt; text-align:center"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Written </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">e</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">vidence from Vertex Pharmaceuticals UK</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold"> (LTC 50)</span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Summary</span></li></ol><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">1.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Vertex’s product </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Kal</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ydeco</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> (</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ivacaftor</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">) </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">is the first in a new class of innovative medicines that treats the underlying causes of </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis, a genetic disease affecting approximately 10,000 people in the UK.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 39.6pt"><span style="color:#ff0000; font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">1.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Kalydeco has been available to all patients with the G551D mutation in England since 1</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> January 2013.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">This has a number of implications for the commissioning and delivery of specialised services for cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">, particularly in relation to NICE’s appraisal process for Highly Specialised Technologies and NHS England’s </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">clinical commissioning policies for higher-cost medicines</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">About </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Vertex</span></li></ol><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">2.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Vertex is a global health sciences company that aims to accelerate the discovery, development, and commercialisation of critical medicines for life-threatening diseases including </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">, hepatitis C, and epilepsy.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 39.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">2.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt">In 1998, Vertex established its first global research and development</span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt">site in the </span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt">UK</span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt">. Researchers at Vertex’s approximately 150-person UK site are focused on discovering new medicines for a variety of cancer types and </span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt">neuroinflammatory</span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> diseases.</span><span style="background-color:#ffffff; font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">About </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Cystic Fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold"> </span></li></ol><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">3.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">a genetic disease</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> affecting </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">approximately </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">10</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">,000 people </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">in the UK.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">It is a complex and multi-system disease that causes the internal organs, particularly the lungs and dig</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">estive system, to produce thick</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> sticky mucus that eventually leads to death from respiratory failure.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">In 2011 t</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">he median age at death for </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">patients </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">was 26 years</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">3.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Cystic fibrosis is also associated with other long-term conditions including </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">diabetes, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">infertility</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">,</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> and osteoporosis.</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">3.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">care of </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">children and adults with </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">is coordinated by specialised services</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> that are directly commissioned by NHS England</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">These specialised services provide </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">care from a multidisciplinary team including specialist doctors, nurses, and allied health professionals.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Kalydeco</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">(</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">Ivacaftor</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">) </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">for Cystic Fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold"> </span></li></ol><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">4.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Vertex’s product </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Kalydeco </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">received regulatory approval for the </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">treatment of </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> in patients aged six years and older who have a G551D mutation in the </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">transmembrane</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> conductance regulator (</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">CFTR</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">)</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> gene from the European Medicines Agency in July 2012.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 39.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">4.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">In 2011 there were 466 cystic fibrosis patients with a copy of this mutation in UK.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Due to this small patient population </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Kalydeco is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">w</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">idely recognised as an ultra-orphan medicine</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">(i.e. a treatment for a very rare disease).</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 39.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">4.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Kalydeco</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">is the first in a new class of innovative medicines </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">that </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">treats </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">the underlying causes of </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The results of clinical trials indicate that treatment with Kalydeco could lead to a 10-year increase in life-expectancy and a significant improvement in quality of life.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">4.4.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Kalydeco</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">has been </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">available to all patients with the </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">G551D mutation in England since 1</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> January 2013 following a commissioning decision made by the Clinical Priorities Advisory Group.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Since 1</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> April 2013 it has been commissioned on a national basis by NHS England.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 13.25pt; padding-left:4.75pt; text-indent:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">NHS Policy Issues</span></li></ol><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">5.1.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">UK clinicians have noted that Kalydeco </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">‘is life changing for the few patients with cystic fibrosis for whom it is indicated’ and, as the first medicine of its kind, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">‘has the potential to transform cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> care’</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">T</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">his </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">transformation in cystic fibrosis care </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">may require </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">changes to the way that specialised services and treatments for the disease are commissioned and delivered.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">National Institute for Health and Care Excellence</span></p><p style="margin:0pt 0pt 0pt 39.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">5.2.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">The National Institute for Health and Care Excellence (NICE) assumed responsibility for the appraisal of H</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ighly Specialised Technologies (i.e. </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">ultra-orphan medicines</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">) </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">on 1</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> April 2013.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">It is essential that NICE’s appraisal process for Highly Specialised Technologi</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">es recognises the value of innovative medicines for th</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">e treatment of very rare clinical subsets of more common diseases, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">particularly long-ter</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">m conditions for which there is </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">no cure, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">and takes this into account when making its recommendations.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt"><a name="_GoBack"></a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:bold">NHS England</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">5.3.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">Although t</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">he majority of medicines for the treatment of cystic fibrosis are funded </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">using </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">the Payment by Results </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">system, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">certain higher-cost medicines are </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">directly commissioned</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> by NHS England.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">It is essential that this direct commissioning continues to ensure </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">cystic fibrosis patients have </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">equitable access to</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> highe</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">r-cost medicines across England</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 0pt 39.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 39.6pt; text-indent:-21.6pt"><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-weight:normal">5.4.</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">I</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">f Kalydeco and other innovative new medicine for cystic fibrosis lead to a reduction in </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">exacerbations and </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">hospital admissions, </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">it may </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">be possible to redesign some services to allow patients to receive a larger proportion of their </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">care </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">in the community</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt">This would be likely to lead to further improvements to patients’ quality of life and reduce the costs of providing specialist services in a hospital setting.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><br /><span style="font-family:'Frutiger LT Std 45 Light'; font-size:11pt; font-style:italic">May 2013</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> Trust.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Annual Data Report 2011 (2013).</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Available at https://www.cysti</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">cystic fibrosis</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">ibrosis.org.uk/media/82506/CR_Annual_Data_Report_2011_Jan_13.pdf</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> NHS England.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Clinical Commissioning Policy: </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Ivacaftor</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> for Cystic Fibrosis (2013).</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Available at http://www.england.nhs.uk/wp-content/uploads/2013/04/a01-p-b.pdf</span></p><p style="margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> Cystic fibrosis Trust.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Annual Data Report 2011 (2013).</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Available at https://www.cysticystic fibrosisibrosis.org.uk/media/82506/CR_Annual_Data_Report_2011_Jan_13.pdf</span></p><p style="margin:0pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> All Wales Medicines Strategy Group.</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Clinical Expert Summary (2013).</span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt"> </span><span style="font-family:'Frutiger LT Std 45 Light'; font-size:9pt">Available at http://www.wales.nhs.uk/sites3/Documents/371/Enc%207%20Appx%203%20ivacaftor%20%28Kalydeco%29%20Clinical%20Expert%20Summary.pdf</span></p></body></html>